The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2015 | A review of current and future directions of clinical trials for CLL
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, reviews the different approaches to the therapy of chronic lymphocytic leukemia (CLL) that are being studied, including a phase 1 trial of lenalidomide plus bendamustine and rituximab (BR) for untreated CLL; a phase 3 trial ibrutinib plus BR for previously treated CLL or small lymphocytic lymphoma; and a phase 3 trial of BR, rituximab and ibrutinib, or ibrutinib alone for older patients with previously untreated CLL.
